Tatva Chintan Pharma [TATVA] vs Grauer & Weil [GRAUWEIL] Detailed Stock Comparison

Tatva Chintan Pharma

NSE

Grauer & Weil

BSE

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Tatva Chintan Pharma wins in 4 metrics, Grauer & Weil wins in 16 metrics, with 0 ties. Grauer & Weil appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	Tatva Chintan Pharma	Grauer & Weil	Better
P/E Ratio (TTM)	357.34	27.36	Grauer & Weil
Price-to-Book Ratio	3.41	4.58	Tatva Chintan Pharma
Debt-to-Equity Ratio	4.93	1.26	Grauer & Weil
PEG Ratio	39.96	38.13	Grauer & Weil
EV/EBITDA	68.14	20.09	Grauer & Weil
Profit Margin (TTM)	1.82%	13.85%	Grauer & Weil
Operating Margin (TTM)	7.15%	7.46%	Grauer & Weil
EBITDA Margin (TTM)	7.15%	7.46%	Grauer & Weil
Return on Equity	0.77%	18.02%	Grauer & Weil
Return on Assets (TTM)	0.68%	8.70%	Grauer & Weil
Free Cash Flow (TTM)	$-516.01M	$999.80M	Grauer & Weil
Dividend Yield	0.21%	1.05%	Grauer & Weil
1-Year Return	5.44%	9.60%	Grauer & Weil
Price-to-Sales Ratio (TTM)	6.38	3.79	Grauer & Weil
Enterprise Value	$25.38B	$37.72B	Grauer & Weil
EV/Revenue Ratio	6.44	3.32	Grauer & Weil
Gross Profit Margin (TTM)	50.07%	41.05%	Tatva Chintan Pharma
Revenue per Share (TTM)	$168	$25	Tatva Chintan Pharma
Earnings per Share (Diluted)	$3.01	$3.47	Grauer & Weil
Beta (Stock Volatility)	0.25	0.28	Tatva Chintan Pharma

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

Tatva Chintan Pharma vs Grauer & Weil Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
Tatva Chintan Pharma	-3.11%	-6.55%	8.95%	44.01%	39.39%	21.27%
Grauer & Weil	1.47%	-0.52%	-8.37%	18.19%	0.93%	-8.46%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
Tatva Chintan Pharma	5.44%	-57.12%	-54.05%	-54.05%	-54.05%	-54.05%
Grauer & Weil	9.60%	47.21%	147.69%	405.77%	1,019.05%	755.68%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

Tatva Chintan Pharma (TATVA): View Full Stock Overview

Grauer & Weil (GRAUWEIL): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: Tatva Chintan Pharma vs Grauer & Weil

Metric	TATVA	GRAUWEIL
Market Information
Market Cap i	₹25.16B	₹43.05B
Market Cap Category	Small cap	Small cap
10 Day Avg. Volume i	499,007	146,830
90 Day Avg. Volume i	267,124	195,422
Last Close	₹1,042.10	₹96.35
52 Week Range	₹621.00 - ₹1,232.75	₹78.00 - ₹120.00
% from 52W High	-15.47%	-19.71%
All-Time High	₹2,977.80 (Nov 01, 2021)	₹204.80 (Feb 26, 2024)
% from All-Time High	-65.00%	-52.95%
Growth Metrics
Quarterly Revenue Growth	0.11%	0.02%
Quarterly Earnings Growth	0.28%	-0.12%
Financial Health
Profit Margin (TTM) i	0.02%	0.14%
Operating Margin (TTM) i	0.07%	0.07%
Return on Equity (TTM) i	0.01%	0.18%
Debt to Equity (MRQ) i	4.93	1.26
Cash & Liquidity
Book Value per Share (MRQ)	₹315.61	₹20.72
Cash per Share (MRQ)	₹6.02	₹11.87
Operating Cash Flow (TTM) i	₹145.88M	₹1.44B
Levered Free Cash Flow (TTM) i	₹57.13M	₹927.08M
Dividends
Last 12-Month Dividend Yield i	0.21%	1.05%
Last 12-Month Dividend i	₹2.00	₹1.00

Valuation & Enterprise Metrics Analysis: Tatva Chintan Pharma vs Grauer & Weil

Metric	TATVA	GRAUWEIL
Price Ratios
P/E Ratio (TTM) i	357.34	27.36
Forward P/E i	39.96	38.13
PEG Ratio i	39.96	38.13
Price to Sales (TTM) i	6.38	3.79
Price to Book (MRQ) i	3.41	4.58
Market Capitalization
Market Capitalization i	₹25.16B	₹43.05B
Enterprise Value i	₹25.38B	₹37.72B
Enterprise Value Metrics
Enterprise to Revenue i	6.44	3.32
Enterprise to EBITDA i	68.14	20.09
Risk & Other Metrics
Beta i	0.25	0.28
Book Value per Share (MRQ) i	₹315.61	₹20.72

Financial Statements Comparison: Tatva Chintan Pharma vs Grauer & Weil

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	TATVA	GRAUWEIL
Revenue/Sales i	₹1.17B	₹3.40B
Cost of Goods Sold i	₹583.46M	₹2.00B
Gross Profit i	₹585.18M	₹1.40B
Research & Development i	N/A	N/A
Operating Income (EBIT) i	₹83.59M	₹237.20M
EBITDA i	₹184.85M	₹417.40M
Pre-Tax Income i	₹91.01M	₹343.50M
Income Tax i	₹24.50M	₹86.10M
Net Income (Profit) i	₹66.51M	₹257.40M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	TATVA	GRAUWEIL
Cash & Equivalents i	₹113.74M	₹1.08B
Total Current Assets i	₹2.65B	₹9.36B
Total Current Liabilities i	₹960.27M	₹2.97B
Long-Term Debt i	₹0	₹37.30M
Total Shareholders Equity i	₹7.39B	₹9.39B
Retained Earnings i	N/A	N/A
Property, Plant & Equipment i	₹5.26B	₹2.47B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	TATVA	GRAUWEIL
Operating Cash Flow i	N/A	N/A
Capital Expenditures i	N/A	N/A
Free Cash Flow i	N/A	N/A
Debt Repayment i	N/A	N/A
Common Stock Repurchase i	N/A	N/A

Short Interest & Institutional Ownership Analysis

Metric	TATVA	GRAUWEIL
Shares Short i	N/A	N/A
Short Ratio i	N/A	N/A
Short % of Float i	N/A	N/A
Average Daily Volume (10 Day) i	499,007	146,830
Average Daily Volume (90 Day) i	267,124	195,422
Shares Outstanding i	23.39M	453.41M
Float Shares i	6.55M	127.47M
% Held by Insiders i	0.72%	0.72%
% Held by Institutions i	0.08%	0.00%

Dividend Analysis & Yield Comparison: Tatva Chintan Pharma vs Grauer & Weil

Metric	TATVA	GRAUWEIL
Last 12-Month Dividend i	₹2.00	₹1.00
Last 12-Month Dividend Yield i	0.21%	1.05%
3-Year Avg Annual Dividend i	₹2.00	₹0.58
3-Year Avg Dividend Yield i	0.14%	0.45%
3-Year Total Dividends i	₹6.00	₹1.73
Ex-Dividend Date	Sep 06, 2024	Aug 06, 2025

Tatva Chintan Pharma [TATVA] vs Grauer & Weil [GRAUWEIL] Detailed Stock Comparison